Citations

Clear

949 citation(s) found for "Li, Bryan".

Proposed changes to the pathologic staging for colon cancer (CC): AJCC Colon Cancer Expert Panel (AJCCCCEP).
Chang, George J. , Pederson, Levi , Asare, Elliot A. , Cohen, Romain , Palis, Bryan E., Shi, Chanjuan , Steele, Scott, Goldberg, Richard M. , Cohen, Romain , Shi, Qian , Jin, Zhaohui , Meyerhardt, Jeffrey A. , André, Thierry , Tie, Jeanne , Dixon, Jesse G. , Ballman, Karla V. , Yothers, Greg , Ma, Zeliang , Alberts, Steven R. , Washington, Mary Kay , Taı̈eb, Julien

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 3520-3520

10.1200/jco.2025.43.16_suppl.3520 Get It

3520 Background: Recent analyses highlight nonhierarchical outcomes using the 8 th Edition AJCC staging system for CC. For instance, the 5-year survival rate for stages I and IIIa patients (pts) closely align. Additionally, tumor deposits (TDs) have been established as significant prognostic indicators. The AJCCCCEP commissioned this study to develop an updated pathological staging system for CC focused specifically on pts without distant metastasis (M0), while retaining the existing stage IV classification. Methods: Individual patient data (IPD) from pts diagnosed with cc (2010- 2017) in the NCDB were divided into training (70%) and internal validation (30%) datasets. External validation used IPD from clinical trials. The primary endpoint was overall survival (OS). Risk classification development for M0 pts incorporated ungrouped data on pathologic T categories, the number of involved regional lymph nodes (LN+), and TD counts. Recursive partitioning and regression tree analyses were applied to construct hierarchical staging levels. Pre-specified criteria required survival probabilities to be consecutive and show clear separations using Kaplan-Meier (KM) estimates with pairwise log-rank test P of < 0.005 for the training and < 0.05 for validation analyses. Results: Data from 281,997 pts (median age 67 years, 50% male, 81% white, 55% T3, 19% T4, 44% N+, 26% M+, and 11% with ≥1 TD) were analyzed, with a median follow-up of 7.3 years. The updated staging system (Table) met pre-specified criteria, with all observed pairwise P < 0.0001 in the development and internal validation sets. KM OS curves displayed a hierarchical separation across all sub-levels after the 1 st year of diagnosis. Consistent results were seen in pts treated with adjuvant chemotherapy in 4 trials (all pair-wise P < 0.0001). Conclusions: The proposed pathological staging system for M0 pts fulfills pre-specified criteria for hierarchical risk stratification, validated both internally and externally, and provides an evidence-based update. Pending review process, the AJCCCCEP will recommend that these changes be made to the Version 9 staging protocol for colon cancer to improve prognostication for CC pts. Stage T, # of LN+, # of TD M % of pts 1y OS (CI), % 3y OS (CI), % 5y OS (CI), % I T1, 0, 0 0 5 96 (95-97) 91 (90-92) 84 (83-86) IIa T2, 0, 0 0 10 95 (94-95) 88 (88-89) 80 (79-81) IIb T1, 0, 1+T1, 1+, 0T2, 0, 1+T2, 1-4, 0T3, 0, 0 0 27 93 (92-93) 84 (84-85) 75 (75-76) IIIa T1, 1+, 1+T2, 1-4, 1+T2, 5+, 0T3, 0, 1+T3, 1-4, 0 0 14 92 (91-92) 80 (80-81) 71 (70-72) IIIb T2, 5+, 1+T3, 1-4, 1+T3, 5+, 0T4a, 0-4, 0T4b, 0-2, 0 0 13 86 (86-87) 69 (68-70) 58 (57-59) IIIc T3, 5+, 1+T4a, 0-4, 1+T4a, 5+, anyT4b, 0-2, 1+T4b, 3+, any 0 5 78 (77-80) 53 (51-54) 40 (38-41) IVa Any 1a 19 59 (58-60) 28 (28-29) 17 (16-18) IVb Any 1b 7 43 (42-44) 14 (13-14) 6 (6-7) CI: 95% confidence internal; Peritoneum involvement data were not available before 2018 in NCDB. Thus, IVa/b were based on 7 th Edition.
Telehealth utilization in neuro-oncology: A single institution experience.
Ser, Hazal, Galloway, Taylor , Baykal, Duru, Hassan, Amna, Valerius, Allison , Campian, Jian , Carabenciov, Ivan D. , Kizilbash, Sani H. , Caron, Samantha, Jones, Jamecca, Burckhard, Jenna L., Markey, Summer, Ruff, Michael W. , Uhm, Joon H. , Neth, Bryan J. , Haddad, Tufia C. , Neth, Byran J. , Kizilbash, Sani H , Baykal, Duru, Hassan, Amna, Lachance, Daniel Honore , Jones, Jamecca, Paludo, Jonas , Pritchett, Joshua C. , Sener, Uğur

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e13893 Get It

e13893 Background: For individuals with CNS tumors who have experience difficulties with in-person (IP) evaluations due to disease-related neurologic disability or the costs associated with travel, telehealth (TH) offers a convenient and timely alternative for accessing specialized neuro-oncology care. We report our institution’s experience with telehealth utilization in neuro-oncology. Methods: We conducted a retrospective review of patients who had at least one neuro-oncology telehealth visit between August 2021 and May 2024 at Mayo Clinic in Rochester, Minnesota. Reasons for visits, outcomes of appointments, acute care utilization following visits was reviewed. Results: A total of 660 patients who had at least one TH visit between August 2021 and May 2024 were included in the analysis. Median age was 56 (range 20-98), 49% were female, and 92% were white. Most patients resided in the US Midwest (84%), followed by the South (8%), West (5%), Northeast (1%), and US Territories (< 1%). Less than two percent were international patients. The most common primary visit diagnosis was glioblastoma (GBM, 26%), followed by astrocytoma, IDH-mutant (17%), meningioma (17%), oligodendroglioma, IDH-mutant, 1p/19q codeleted (7%). Of 6657 visits reviewed, 2745 (41%) were conducted via TH. Telehealth visits served various purposes, including consultation for newly diagnosed tumors or abnormal MRIs (n = 26), second opinion for an established tumor diagnosis (n = 119), discussion about clinical trial participation (n = 108), tumor-related treatment discussions (n = 719), chemotherapy education (n = 161), new symptom assessment (n = 117), symptom management (n = 366), and tumor surveillance (n = 1694). Outcomes from telehealth visits included enrollment in clinical trials (n = 28), proceeding with tumor-directed surgery (n = 46), initiation of radiation therapy (n = 88), starting or changing systemic therapy (n = 377), continuing existing systemic therapy (n = 932), transition to supportive care (n = 45), tumor diagnostic workup (n = 28), continuation of tumor surveillance (n = 1254). Acute care utilization, defined as an emergency department visit or hospitalization within one month of an appointment, was the same following telehealth visits compared to in-person visits (6.9% for IP vs 5% for TH, p = 0.507). Conclusions: Our findings demonstrate that telehealth can effectively support all aspects of neuro-oncology care, ranging from initial diagnosis discussions to systemic therapy management and transitions to supportive care. Telehealth offers a convenient and accessible method of care delivery option for patients faced with neurologic illness. Additionally, THs do not lead to increased acute care utilization compared to IP evaluations.
Neuro-oncology anywhere: Preliminary results from a decentralized clinical trial aimed at improving neurocognitive outcomes in patients with CNS malignancy.
Neth, Bryan J. , Alden, Eva , Galloway, Taylor , Hughes, Heather , Flickinger, Lynn M. , Chan, Katrina, Breen, William G. , Kizilbash, Sani H. , Campian, Jian , Uhm, Joon H. , Ruff, Michael W. , D’Andre, Stacy D. , Burns, Terence, Stricker, John L. , Geyer, Susan M. , Breutzman, Emily, Kottschade, Becky, Haddad, Tufia C. , Chan, Katrina , Neth, Byran J. , Kizilbash, Sani H , Kottschade, Becky, Stricker, Nikki H. , Sener, Uğur

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e13891 Get It

e13891 Background: Most patients with central nervous system (CNS) malignancy develop cognitive impairment, fatigue, and mood-related symptoms that are impacted by cancer and treatment, including radiation therapy. We currently have limited therapies to mitigate neurocognitive toxicity. It is important to accurately assess neurocognitive function and symptom burden when working to establish therapeutics. The objective of this trial is to assess the effectiveness of therapies aimed at improving neurocognitive function and quality of life by leveraging a decentralized approach incorporating an established digital neurocognitive assessment tool and development of a remote symptom collection/medication log to improve capture of longitudinal neurocognitive data. Methods: This is an open-label decentralized clinical trial (NCT06377696) that randomizes patients who have received intracranial radiation for primary and secondary brain tumors in a 1:1 allocation to health promotion with a wearable device +/- metformin (targeting radiation-related toxicity). Remote symptom collection is reported through digital patient surveys. Medication adherence is being monitored through a digital medication log developed for the study. Remote neurologic examination is performed by clinical neuro-oncologists at telehealth visits. Participants perform serial remote cognitive assessments with an established digital neurocognitive testing platform – Mayo Test Drive (MTD). Cognitive assessments and symptom surveys were designed to be completed on a smartphone, tablet, or computer device. Results: The study started enrollment on May 31, 2024. As of January 27, 2025, 54 of 100 planned participants have enrolled (27 on each arm). 51 participants remain active on trial; 3 withdrew from trial participation (2 prior to treatment, 1 after treatment). The overall completion rate for a quality-of-life questionnaire (EORTC QLQ-C30) is 85.0%, and each dose of metformin logged is 78.5%. The overall completion rate for virtual neurologic examination and short test of mental status is 94.7%. For MTD, the overall completion rate is 97.9%. The average MTD session duration was 16 minutes. Most participants completed MTD testing using a smartphone (90.5%) at home (89.1%). Conclusions: These results provide preliminary support that a decentralized trial assessing neurocognitive outcomes is feasible in patients with CNS malignancy. The completion rates of questionnaires and objective cognitive evaluation are comparable or higher than expected with historic norms. Final study results will provide real-world cognitive and quality-of-life data for patients with CNS tumors while providing preliminary data on the effectiveness of device-based health promotion +/- metformin for treatment related cognitive decline. Clinical trial information: NCT06377696 .
The impact of IDH mutation and 1p/19q codeletion on immune-checkpoint inhibitor efficacy in recurrent gliomas.
Shafqat, Shameel , Burns, Terence, Campian, Jian , Hammack, Julie E., Mrugała, Maciej M. , Neth, Bryan J. , Porter, Alyx B. , Ruff, Michael W. , Uhm, Joon H. , Kizilbash, Sani H. , Neth, Byran J. , Kizilbash, Sani H , Maqbool, Muhammad Asad , Ensign, Shannon P. Fortin , Galanis, Evanthia , Sener, Uğur , Sherman, Wendy

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 2053-2053

10.1200/jco.2025.43.16_suppl.2053 Get It

2053 Background: Recurrent gliomas are highly aggressive brain tumors, often resistant to conventional treatments. Immune checkpoint inhibitors (ICI) have emerged as promising therapeutic agents by targeting tumor cells through immune modulation. However, clinical trials have demonstrated limited efficacy in recurrent gliomas. This study aimed to identify potential factors influencing treatment efficacy of ICIs in recurrent gliomas. Methods: This retrospective study, conducted across the Mayo Clinic following IRB approval, included patients ≥ 18 years diagnosed with adult-type diffuse gliomas. Eligible patients received treatment with at least 2 cycles of ICI for recurrent glioma between 2014 – 2024. Patients treated with ICIs as initial therapy were excluded. Clinical, radiographic, histological, and molecular data were analyzed, with missing information excluded. Responders to ICI were defined as patients who did not meet iRANO criteria for progressive disease based on first radiographic response assessment (and confirmatory follow up imaging as needed for possible pseudo-progression). Survival outcomes [Progression-Free Survival (PFS) and Overall Survival (OS)] and potential predictive variables were analyzed using the Kaplan-Meier method and Cox-Regression Analyses. Results: 67 patients met eligibility criteria (mean age: 45.1 ± 15.0 years; 64.2% male; 94% white). 64 (95.5%) patients received Pembrolizumab, 2 (3%) Nivolumab, and 1(1.5%) combined Ipilimumab/Nivolumab, with a median treatment duration of 2.77 (1.39 – 19.4) months. All had prior alkylating chemotherapy. The OS (from diagnosis) for IDH wildtype (IDH-WT, n = 36), IDH mutant, 1p/19q non-co-deleted (IDH-MUT, n = 17) and IDH mutant, 1p/19q co-deleted (OLIGO, n = 14) gliomas were 3.1, 9.2, and 18.6 years, respectively. The median PFS from time of ICI was 2.23 (0.69 – 27.3) months. 24 (36.9%) patients were identified as Responders. PFS was not significantly different between patients with IDH-MUT and IDH-WT gliomas (2.30 vs 2.07 months, p = 0.593). However, patients with OLIGO gliomas had a significantly higher PFS compared to IDH-WT gliomas (5.16 vs 2.07 months, p = 0.021). The proportion of responders was greatest in OLIGO gliomas, however, did not reach statistical significance (IDH-WT, 31.4%; IDH-MUT, 29.4%; OLIGO, 61.5%, p = 0.120). Overall PFS was not impacted by patient age, sex, and extent of initial resection. When analyses were limited to Responders, the PFS for IDH-WT, IDH-MUT and OLIGO gliomas were 5.75, 7.01 and 10.8 months, respectively ( p = 0.434). Conclusions: Patients with recurrent OLIGO gliomas may have a longer PFS with ICI therapy compared with recurrent IDH-WT and IDH-MUT gliomas. However, there is significant variability in ICI treatment efficacy between patients. Further molecular profiling is in progress to evaluate additional predictive biomarkers of response.
Neuro-oncology anywhere 242: Pilot study evaluating telehealth and in-person assessments in patients with glioma receiving oral chemotherapy—Clinical trial in progress.
Galloway, Taylor , Schultz, Sydney , Hughes, Heather, Steinmetz, Sue, Tauer, William, Mason, Charles W. , Huebert, Carey, Mead‐Harvey, Carolyn , Walt, Charles Van Der , Geyer, Susan M. , Uhm, Joon H. , Campian, Jian , Kizilbash, Sani H. , Neth, Bryan J. , Breen, William G. , Lehrer, Eric J. , Burns, Terence, Kottschade, Becky, Haddad, Tufia C. , Neth, Byran J. , Kizilbash, Sani H , Sener, Uğur , Hughes, Heather, Mason, Charles, Walt, Charles Van Der

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.tps2099 Get It

TPS2099 Background: Gliomas are the most common primary central nervous system (CNS) malignancy in adults, accounting for 26.3% of all brain tumors. Care at high volume centers is associated with an overall survival benefit, but access to in-person evaluations can be challenging due to disease-related neurological disability and loss of income. Telehealth represents a convenient and efficient alternative to in-person evaluations, but acceptability and comparative safety of this care delivery modality has not been prospectively evaluated among glioma patients undergoing chemotherapy. Methods: This single-arm non-randomized pragmatic clinical trial evaluates patient satisfaction with, and safety of video-enabled telehealth assessments compared to in-person evaluations for patients with glioma undergoing temozolomide chemotherapy. The study includes adult patients with a diagnosis of glioma requiring adjuvant temozolomide chemotherapy. Participants act as their own controls, alternating between in-person and telehealth assessments while undergoing chemotherapy dosed per standard of care. Monitoring labs are completed locally and transmitted electronically. For participants without access to Wi-Fi or a device (e.g. mobile phone or computer), cellular-enabled tablet devices are provided to facilitate appointments and completion of electronic study components. All participants who travel to in-person appointments are reimbursed for travel expenses. The primary outcome measure is patient satisfaction with care delivered, as measured by institutional Press-Ganey survey scores obtained following telehealth and in-person assessments. A key secondary outcome measure is completion rate of planned oral chemotherapy, tracked using a digital pill diary incorporated into our institutional electronic health record. The digital diary allows real-time tracking of chemotherapy adherence and adverse events experienced by participants. Other secondary outcomes include acute care utilization days following telehealth and in-person visits (defined as emergency department evaluations and days of inpatient stay), neurologic disability as measured by the Neurologic Assessment in Neuro-Oncology (NANO) scale, and disease related quality of life measured by the EORTC QLQ-C30. All participant surveys are self-reported and completed electronically. This decentralized pragmatic clinical trial provides unprecedented, prospective real-world data on utilization of telehealth services compared to in-person visits for patients undergoing chemotherapy for glioma. We expect the data generated to inform the design and conduct of future decentralized interventional neuro-oncology trials. NCT06625047 opened for enrollment in October 2024, 16 of 30 intended participants were accrued as of January 2025. Clinical trial information: NCT06625047 .
Retifanlimab with bevacizumab and hypofractionated radiotherapy to treat recurrent glioblastoma.
Karbhari, Nishika , Geyer, Susan M. , Chheda, Milan G. , Ruff, Michael W. , Kizilbash, Sani H. , Uhm, Joon H. , Neth, Bryan J. , Lehrer, Eric J. , Breen, William G. , Yan, Elizabeth , Mahajan, Anita , Brown, Paul D. , Campian, Jian , Neth, Byran J. , Kizilbash, Sani H , Karbhari, Nishika , Ulrich, Angela, Sherman, Wendy , Ensign, Shannon P. Fortin , Strowd, Roy E. , Sener, Uğur , Galanis, Evanthia

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.tps2092 Get It

TPS2092 Background: Glioblastoma (GBM) is the most common primary brain malignancy in adults. GBM is universally recurrent and associated with dismal outcomes. Re-irradiation (reRT) is ideal for evaluating combination therapy for recurrent GBM (rGBM) due to its multifactorial mechanism of action, including downstream immunomodulatory activity. RT (especially multi-fraction) increases immunogenicity in preclinical models by promoting immune activation, immune migration, and antigen uptake. Additionally, a recent study demonstrated enhanced PD-L1 expression in the glioma tumor microenvironment (TME) following RT, and combining stereotactic RT with a PD-1 inhibitor improved survival in murine models. Retifanlimab is a humanized monoclonal anti-PD1 IgG4 antibody that received FDA approval for adults with metastatic or recurrent locally advanced Merkel cell carcinoma. Bevacizumab, an anti-VEGF antibody, is a treatment for radiation necrosis/cerebral edema with less immune suppression than corticosteroids. In a previous Phase 2 study, hypofractionated RT (HFRT), retifanlimab, and bevacizumab was associated with a 9-month overall survival (OS) rate of 71.4%. To demonstrate the efficacy of this regimen compared to HFRT and bevacizumab, we have designed a new randomized controlled Phase 2 trial. We hypothesize that combination reRT with retifanlimab will produce a more robust anti-tumor immune response and improve OS compared to reRT without retifanlimab. Methods: This is a multicenter, open-label, randomized, controlled Phase 2 study of retifanlimab, bevacizumab, and HFRT for adult patients with rGBM. Patients are randomized 1:1 to the experimental (bevacizumab + retifanlimab + HFRT) or control cohort (bevacizumab + HFRT). Key eligibility criteria include age ≥ 18 years, Karnofsky performance status ≥ 60, ≥ 4 months since administration of any prior bevacizumab, and dexamethasone dose ≤ 4 mg at the time of randomization. The primary endpoint is 9-month OS. Secondary endpoints include OS, progression-free survival, objective response rate, neurologic assessment by NANO criteria, and adverse events profile. Protocol treatment will continue up to two years, or until progression or intolerable toxicity. Survival follow up will continue every two months, up to four years. Seven of the planned 94 patients have been enrolled as of submission on 1/28/25. Clinical trial #: NCT06160206. Funding provided by Incyte. Clinical trial information: NCT06160206 .
Longitudinal neuropsychological evaluation allows diagnosis of MCI with less severe memory change
Locke, Dona E.C. , Langlais, Blake, Woolston, Dixie J., Woodruff, Bryan K. , Stonnington, Cynthia M. , Baxter, Leslie A., Caselli, Richard J. , Woolston, Dixie, Locke, Dona E C , Baxter, Leslie

Mayo Clinic

Alzheimer's & Dementia | May 23, 2025 | Volume: 21 | Issue: 5 | Pages: No page available

10.1002/alz.70317 | PMID 40410931 Get It

AbstractINTRODUCTIONWe previously demonstrated that single‐domain amnestic mild cognitive impairment (SDAm‐MCI) detected through longitudinal neuropsychological testing in our research cohort is less severe than in clinically incident symptomatic individuals. This study aims to replicate and expand this work using a National Alzheimer's Coordinating Center dataset.METHODSParticipants were classified into two groups: those enrolled with normal cognition (Normal Enrollees) and those enrolled with SDAm‐MCI (Amnestic Enrollees). Groups were compared at the time of diagnosis and on rates of cognitive decline post‐diagnosis.RESULTSAt SDAm‐MCI diagnosis, Normal Enrollees were 17% to 39% less impaired on memory tasks, after which the slope of change over time steepened compared to their pre‐symptomatic change and was steeper than in Amnestic Enrollees.DISCUSSIONIncident MCI detected through longitudinal neuropsychological testing is initially milder but may progress more steeply than in clinically established MCI. Sensitive assessment of cognitive decline is essential for capturing early changes that are more likely to be amenable to therapeutic treatment.Highlights Longitudinal cognitive evaluation detects symptomatic Alzheimer's disease earlier than mental status exams. At the time of diagnosis, converters were less impaired compared to initially symptomatic patients. Converters’ cognition declined more steeply than initially symptomatic patients. Sensitive cognitive tests are essential to capture early changes, given new disease‐modifying therapies.
Three Hundred Periprosthetic Tibial Fractures Around a Total Knee Replacement
Dugdale, Evan M. , Alter, Thomas D. , Stuart, Michael J. , Sems, S.A. , Yuan, Brandon J. , Spangehl, Mark J. , Springer, Bryan D. , Berry, Daniel J. , Abdel, Matthew P. , Sems, Stephen A , Abdel, Matthew P , Stuart, Michael J , Yuan, Brandon , Berry, Daniel J , Spangehl, Mark

Mayo Clinic

Journal of Bone and Joint Surgery | May 23, 2025 | Volume: 107 | Issue: 14 | Pages: 1579-1589

10.2106/jbjs.24.01407 | PMID 40408445 Get It

Background: Periprosthetic tibial fractures around a total knee replacement (TKR) remain challenging to manage, with little published information for guidance. The purpose of this study was to review the types, management techniques, and outcomes of periprosthetic tibial fractures in the largest series to date. Methods: We identified 300 periprosthetic tibial fractures (285 patients) around a TKR (43% in primary TKRs and 57% in revision TKRs) sustained between 1996 and 2020. Fractures were classified according to Felix et al. as Type I (tibial plateau), Type II (adjacent to stem), Type III (distal to stem), or Type IV (tibial tubercle), with subtypes A (well-fixed component), B (loose component), and C (intraoperative fracture). Of the fractures in this study, 53% were Type I, 24% were Type II, 16% were Type III, and 8% were Type IV. A total of 46% of fractures occurred intraoperatively, and 54% of fractures occurred postoperatively (61% subtype A, 39% subtype B). The mean patient age at fracture was 67 years, and 64% of patients were female. The mean follow-up was 6 years. Results: The intraoperative fracture incidence was 1.40% in revision TKRs and 0.10% in primary TKRs. Among intraoperative fractures, the 2-year survivorship free from tibial component revision was highest in Type I (100%) and lowest in Type IV (67%) (p < 0.001). For postoperative fractures, the 2-year survivorship free from any reoperation was 29% and the 2-year survivorship free from tibial component revision was 51%. Type-I postoperative fractures had the lowest 2-year survivorship free from tibial component revision (10%), whereas Type-III fractures had the highest survivorship (88%) (p < 0.001). Conclusions: Intraoperative periprosthetic fracture of the tibia was fourteenfold more likely in revision TKRs compared with primary TKRs. Among all intraoperative fractures, Type-I fractures were well-tolerated, with 100% survivorship free from tibial component revision at 2 years. Conversely, Type-I postoperative fractures had only 10% survivorship at 2 years. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
The International Classification of Vestibular Disorders: Achievements, challenges, and future directions
Kaski, Diego , Tarnutzer, Alexander A. , Carey, John P. , Cha, Yoon‐Hee , Eggers, Scott D.Z. , Furman, Joseph M. , Kim, Hyun Ah , Lempert, Thomas , López‐Escámez, José A. , Magnusson, Måns , Newman‐Toker, David E. , Seemungal, Barry M. , Berg, Raymond van de , Brevern, Michael von , Bisdorff, Alexandre , Cha, Y H , Eggers, Scott Dz, Lempert, Thomas , López-Escámez, Jose A , Magnusson, Mans , Newman-Toker, David E , Seemungal, Barry M , Staab, Jeffrey P , Agrawal, Yuri , Kim, Ji‐Soo , Staab, Jeffrey P. , Strupp, Michael Leo , Ward, Bryan Kevin

Mayo Clinic

Journal of Vestibular Research | May 17, 2025 | Volume: 35 | Issue: 3 | Pages: 105-112

10.1177/09574271251313803 | PMID 39973600 Get It

In 2007, the Bárány Society embarked on a project to establish definitions of vestibular syndromes and disorders based on best available evidence, referred to as the International Classification of Vestibular Disorders (ICVD). Since then, numerous publications providing consensus-driven diagnostic criteria for vestibular symptoms, syndromes, and disorders have been published. Here, we reflect on the rationale for developing the ICVD as well as its subsequent achievements, challenges, and outlook. In this summary of the work of the ICVD to date, the authors will focus on practical aspects to help improve the utility and applicability of these diagnostic criteria moving forward.
Evaluating changes in the breast cancer-related quality of life of young women with breast cancer: long-term results from a multicenter prospective cohort
Vaca‐Cartagena, Bryan F. , Mesa-Chávez, Fernanda , Azim, Hatem A. , Platas, Alejandra , Fonseca, Alan , Cruz‐Ramos, Marlid , Rodríguez, Ana María , Mohar, Alejandro , Guajardo, Ana S Ferrigno , Villarreal-Garza, Cynthia , Rotolo, Federico , Rodriguez, Ana, Villarreal‐Garza, Cynthia

Mayo Clinic

Therapeutic Advances in Medical Oncology | May 16, 2025 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/17588359251337493 | PMID 40386468 Get It

Background: Young women with breast cancer (YWBC) typically undergo intensive treatment that negatively impacts their quality of life (QoL). However, limited information is available on how their QoL changes, as most research has focused on older patients. Objectives: To assess changes in QoL among YWBC, identify the most affected QoL domains, and identify the factors associated with these changes. Design: Joven & Fuerte is a multicenter cohort of women aged ⩽40 in Mexico with newly diagnosed BC from 2014 to 2020. Methods: Participants completed the European Organization for Research and Treatment of Cancer Breast Cancer module QLQ-BR23 questionnaire at five different time points from enrollment until year 5 postdiagnosis. Clinical and treatment data were also collected. Group-based multivariate trajectory modeling was used to analyze longitudinal changes across QoL domains and classify patients into appropriate groups. Logistic models were then employed to identify associations between variables and group classification. Results: A total of 477 women (median age: 36 years; interquartile range 32–38) were included. Most had public health insurance (87%) and were diagnosed with stage II (49%) or III (39%) BC. Two trajectory groups, namely, “good” and “poor,” were identified based on QLQ-BR23 scores. Most patients ( n = 294, 62%) were in the poor group. In the good group, sexual enjoyment scores remained stable from baseline to year 5 (51.4), whereas those in the poor group decreased (51.0–37.3). Distress related to hair loss over time declined, with scores decreasing from 36.3 to 27.0 in the good trajectory group and from 43.4 to 31.2 in the poor trajectory group. For future perspective, the good group improved from 56.4 to 79.0, while the poor group increased from 39.3 to 57.2. Patients with human epidermal growth factor receptor 2-positive BC (adjusted odds ratio (aOR) = 0.57, 95% confidence interval (CI) 0.35–0.94, p = 0.028) and those with public health insurance (aOR = 0.41, 95% CI 0.16–0.90, p = 0.035) were less likely to belong to the poor trajectory group. Conclusion: A high proportion of YWBC experience a poor QoL trajectory over time, particularly in areas related to sexual health, future perspective, and hair loss.